We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Avalon Announces Expiration of the Sanofi-Aventis Agreement
News

Avalon Announces Expiration of the Sanofi-Aventis Agreement

Avalon Announces Expiration of the Sanofi-Aventis Agreement
News

Avalon Announces Expiration of the Sanofi-Aventis Agreement

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Avalon Announces Expiration of the Sanofi-Aventis Agreement"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Avalon Pharmaceuticals, Inc. has announced the expiration of its agreement with sanofi-aventis. The agreement in December 2003 established a collaboration to utilize molecular cytogenetics to identify and validate oncology targets.

The agreement expired as a result of sanofi- aventis' decision not to advance targets that were a focus of the collaboration for further validation.

"We have appreciated the close collaboration with sanofi-aventis on this program," said Paul Young, Ph.D., Vice President of Research for Avalon.

"While they did not select any targets from this program, we expect to continue validation studies on several of the genes as potential Avalon drug discovery targets."

Advertisement